期刊文献+

石杉碱甲聚乳酸-乙醇酸纳米粒的制备、表征及其小鼠活体成像脑靶向分布 被引量:4

Preparation,characterization and brain targeting efficiency in mice of huperzine A-PLGA nanoparticle
下载PDF
导出
摘要 目的制备石杉碱甲(HupA)聚乳酸-乙醇酸共聚物(PLGA)纳米粒,并研究其分布特性。方法以PLGA为载体材料,采用乳化溶剂挥发法,正交实验优化HupA-PLGA纳米粒的制备工艺;透射电子显微镜观察纳米粒形态;激光粒度仪测定平均粒径、粒径分布和Zeta电位;HPLC法测定纳米粒的包封率;并通过小动物活体荧光成像实验对纳米粒在小鼠体内的分布特性进行研究。结果优化条件下制备的纳米粒呈圆形,大小较为均一,平均粒径为(46.49±1.37)nm,多分散指数值为0.31±0.01,Zeta电位为(-38.3±1.56)mV,包封率为(28.45±1.52)%,且工艺重现性好。小动物活体成像实验结果表明该纳米粒可以通过血脑屏障到达脑组织,且具有很好的缓释作用。结论以PLGA为载体的HupA纳米粒具有较小的粒径、良好的缓释性能并能提高脑内药物浓度水平。 Objective To prepare huperzine A ( HupA ) -poly ( lactic-co-glycolic acid ) (PLGA) nanoparticles ( HupA-PLGA- NP) and to study their distribution property in mice. Methods HupA-PLGA-NP were prepared by emulsion solvent evaporation meth- od with PLGA as the carrier material, and the formulations were optimized by orthogonal design test. Nanoparticles were characterized by transmission electron microscopy ( TEM ) and laser particle diameter analyzer. Encapsulation efficiency ( EE ) was detected by HPLC. Distribution of nanoparticles in mice was evaluated by in vivo imaging system. Results The nanoparticles prepared by the opti- mal preparation were uniform spherical particles by TEM. Mean diameter, polydisperse index and Zeta potential of nanoparticles were (46. 49 ± 1.37) nm, (0. 31 ± 0. 01 ) and ( - 38. 3 ± 1.56) mV, respectively. EE was (28.45 ± 1.52) %. The verifying experiments indicated that the repeatibility of the experiment was satisfactory. Results of in vivo imaging confirmed that nanoparticles with the diam- eter of about 50 nm could cross blood-brain barrier into brain and had good sustained-release effect. Conclusion HupA-PLGA-NP are found to have smaller particle size, sustained release of HupA and elevated drug concentration in brain.
机构地区 防化研究院
出处 《国际药学研究杂志》 CAS CSCD 2014年第2期221-226,共6页 Journal of International Pharmaceutical Research
关键词 石杉碱甲 聚乳酸-乙醇酸 正交实验 纳米粒 活体成像 huperzine A poly( lactic-co-glycolic acid) orthogonal design test nanoparticles in vivo imaging
  • 相关文献

参考文献15

  • 1任晓蕾,张海英,李玉珍.石杉碱甲治疗轻、中度阿尔茨海默病有效性和安全性的Meta分析[J].中国药房,2010,21(10):909-913. 被引量:21
  • 2Grunwald J, Raveh L, Doctor P, et al. Huperzine A as a pre- treatment candidate drug against nerve agent toxicity [ J ]. Life Sci, 1994, 54(14) :991-997.
  • 3Lallement G, Veyret J, Masqueliez M, et al. Efficacy of hu- perzine in preventing soman induced seizures, neuropathological changes and lethality[ J]. Fund Clin Pharmacol, 1997, 11 (5) : 387-394.
  • 4Tonduli L, Testylier G, Masqueliez C, et al. Effects of huperzine used as pretreatment against solnan-induced seizures [ J ]. Neuro Toxicol, 2001, 22(1 ):29-37.
  • 5Cooper DL, Harirforoosh S. Design and optimization of PLGA-based diclofenac loaded nanoparticles [ J ]. PLoS One, 2014, 9 ( 1 ) : e87326.
  • 6Zhu H, Chen H, Zeng X, et al. Co-delivery of chemotherapeutic drags with vitamin ETPGS by porous PLGA nanoparticles for en- hanced chemotherapy against multi-drug resistance[J]. Biomate- rials, 2014, 35(7):2391-2400.
  • 7Ghasemian E, Vatanara A, Rouini MR, et al. Preparation,char- acterization and optimization of sildenafil citrate loaded PLGA nanoparticles by statistical factorial design [ J]. Daru, 2013, 21 (1) :68.
  • 8Li JW, Feng L, Fan L, et al. Targeting the brain with PEGePL- GA nanoparticles modified with phage-displayed peptidcs [ J ]. Biomaterials, 2011, 32(21 ) :4943-4950.
  • 9Ragelle H, Riva R, Vandermculen G, et al. Chitosan nanoparti- cles for siRNA delivery : optimizing formulation to increase stabili- ty and efficiency[ J]. J Control Release, 2014, 176:54-63.
  • 10张晶,张鉴,邓树海.纳米粒体内靶向性的研究进展[J].山东医药,2006,46(35):75-76. 被引量:4

二级参考文献33

共引文献46

同被引文献103

  • 1朱瀛,陆伟根.磁性微球和磁性纳米粒的研究进展[J].中国医药工业杂志,2005,36(9):581-584. 被引量:24
  • 2陶涛,岳鹏,赵雁,张春娜,陈庆华.石杉碱甲鼻用原位凝胶喷雾剂的制备及稳定性研究[J].中国新药杂志,2006,15(22):1950-1954. 被引量:9
  • 3张少卓,陆小左.抗阿尔茨海默病中药的药理研究进展[J].中医脑病杂志,2011,7(4):219-222.
  • 4Gao H, Pang Z, Jiang X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system[J].Pharm Res, 2013, 30(10): 2485-2498.
  • 5Orthmann A, Fichtner I, Zeisig R. Improving the transport of chemotherapeutic drugs across the blood-brain barrier[J].Expert Rev Clin Pharmacol, 2011, 4(4): 477-490.
  • 6Hu K, Shi Y, Jiang W, et al. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson′s disease[J].Int J Pharm, 2011, 415(1/2): 273-283.
  • 7Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery[J].Curr Drug Deliv, 2012, 9(6): 566-582.
  • 8Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system[J].Adv Drug Deliv Rev, 2012, 64(7): 614-628.
  • 9Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting[J].Expert Opin Drug Deliv, 2013, 10(7): 957-972.
  • 10Li X, Du L, Chen X, et al. Nasal delivery of analgesic ketorolac tromethamine thermo-and ion-sensitive in situ hydrogels[J].Int J Pharm, 2015, 489(1/2): 252-260.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部